Insider · CIK 0001685994

Cumbo Alexander

Reports to the SEC for 7 companies · BEDFORD, MA

sec.gov

Transactions

Companies

Filings

CIK

0001685994

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-09-23	STOKStoke Therapeutics, Inc. · Director Stock Option (Right to Buy)A Award	Director	AAward	+39.7K sh	—	—	39,674
2026-06-11	VORVor Biopharma Inc. · Stock option (right to buy)A Award	Director	AAward	+56.3K sh	—	—	56,345
2026-06-05	CLYMClimb Bio, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2026-02-18	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−16.6K sh	$5.82	−$96.9K	235,405
2026-02-13	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−30K sh	—	—	60,063
2026-02-13	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+30K sh	—	—	252,049
2026-02-04	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−48.9K sh	$6.44	−$315K	222,018
2026-02-02	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−80.3K sh	$6.44	−$517K	270,931
2026-01-31	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−100K sh	—	—	301,200
2026-01-31	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+100K sh	—	—	351,189
2026-01-29	SLDBSolid Biosciences Inc. · Performance Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−169K sh	—	—	0
2026-01-29	SLDBSolid Biosciences Inc. · Employee Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+510K sh	—	—	509,850
2026-01-29	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+169K sh	—	—	250,789
2026-01-29	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+169K sh	—	—	169,401
2026-01-29	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+255K sh	—	—	254,900
2025-12-03	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−10.8K sh	$5.11	−$55.2K	81,388
2025-12-02	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+28.6K sh	—	—	92,196
2025-12-02	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−28.6K sh	—	—	28,613
2025-08-14	SLDBSolid Biosciences Inc. · Employee Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+338K sh	—	—	337,500
2025-08-14	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+169K sh	—	—	168,750
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−136K sh	—	—	0
2025-07-25	Verve Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Director	DDisposition to Issuer	−42.2K sh	—	—	0
2025-07-16	VORVor Biopharma Inc. · Stock Option (right to buy)A Award	Director	AAward	+60K sh	—	—	60,000
2025-06-05	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+42.2K sh	—	—	42,200
2025-06-04	CLYMClimb Bio, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+40K sh	—	—	40,000
2025-03-28	CLYMClimb Bio, Inc. · Stock Option (Right to Buy)A Award	Director	AAward	+80K sh	—	—	80,000
2025-02-14	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−11.4K sh	$3.96	−$45K	60,717
2025-02-13	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−30K sh	—	—	90,094
2025-02-13	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+30K sh	—	—	72,082
2025-01-31	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+402K sh	—	—	401,600
2024-12-03	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−11.1K sh	$5.60	−$62.2K	38,484
2024-12-02	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+28.6K sh	—	—	49,598
2024-12-02	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−28.6K sh	—	—	57,225
2024-06-26	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+136K sh	—	—	136,139
2024-02-13	SLDBSolid Biosciences Inc. · Employee Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+240K sh	—	—	240,250
2024-02-13	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+120K sh	—	—	120,125
2023-12-04	SLDBSolid Biosciences Inc.S Sale	Director, President and CEO	SSale	−11.8K sh	$2.77	−$32.5K	17,439
2023-12-02	SLDBSolid Biosciences Inc. · Restricted Stock UnitsM Exercise/Conversion	Director, President and CEO	MExercise/Conversion	−28.6K sh	—	—	85,837
2023-12-02	SLDBSolid Biosciences Inc.M Exercise/Conversion	Director, President and CEO	MExercise/Conversion	+28.6K sh	—	—	29,196
2023-06-15	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+26.6K sh	—	—	26,642
2022-12-02	SLDBSolid Biosciences Inc.A Award	Director, President and CEO	AAward	+584 sh	—	—	584
2022-12-02	SLDBSolid Biosciences Inc. · Restricted Stock UnitsA Award	Director, President and CEO	AAward	+114K sh	—	—	114,449
2022-12-02	SLDBSolid Biosciences Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+229K sh	—	—	228,900
2022-06-09	Verve Therapeutics, Inc.Stock Option (right to buy)A Award	Director	AAward	+31K sh	—	—	31,000
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−25K sh	—	—	0
2020-04-02	Ra Pharmaceuticals, Inc.Stock Option (Right to Buy)D Disposition to Issuer	Director	DDisposition to Issuer	−15K sh	—	—	0
2020-02-28	SRPTSarepta Therapeutics, Inc.A Award	EVP, Chief Commercial Officer	AAward	+6,700 sh	—	—	8,567
2020-02-28	SRPTSarepta Therapeutics, Inc. · Stock option (right to buy)A Award	EVP, Chief Commercial Officer	AAward	+37.5K sh	—	—	37,500
2019-12-13	SRPTSarepta Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+2,727 sh	$13.71	+$37.4K	13,888
2019-12-13	SRPTSarepta Therapeutics, Inc.M Exercise/Conversion	EVP, Chief Commercial Officer	MExercise/Conversion	+26.1K sh	$26.24	+$684K	43,867

Recent filings

Accepted (ET)
Sep 254
Cumbo Alexander0001685994-26-000009
SEC(opens sec.gov)
Jun 124
Cumbo Alexander0001193125-26-269997
SEC(opens sec.gov)
Jun 84
Cumbo Alexander0001193125-26-262281
SEC(opens sec.gov)
Apr 214
Cumbo Alexander0001193125-26-166735
SEC(opens sec.gov)
Feb 184
Cumbo Alexander0001193125-26-057878
SEC(opens sec.gov)
Feb 64
Cumbo Alexander0001193125-26-041519
SEC(opens sec.gov)
Feb 24
Cumbo Alexander0001193125-26-034087
SEC(opens sec.gov)
Dec 44
Cumbo Alexander0001193125-25-308115
SEC(opens sec.gov)
Aug 184
Cumbo Alexander0000950170-25-109723
SEC(opens sec.gov)

Companies

Address

C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE

BEDFORD, MA, 01730